After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....